Vancouver, BC –May, 2019 - Medipure Holdings. Inc., parent company of Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Rman Walia, CPA, CA as its Corporate Controller.
Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Alan C. Mendelson as Corporate Secretary and Advisor to the Board of Directors.
Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Ognjen Brborović to its Scientific Advisory Board.
Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Miroslav Weiss as Medical Director of its subsidiary in Croatia.
Vancouver, BC – October 29, 2018: Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Dubravko Kičić as Director of Operations for its Croatian subsidiary.
Vancouver, BC. On August 24, 2018, the Office of Controlled Substances (OCS), Health Canada granted Medipure Pharmaceuticals Inc. a full Level 6 Dealer's License for Controlled Substances pursuant to the Controlled Drugs and Substances Act, subject to an annual renewal process.
Vancouver, BC – Medipure Holdings Inc. is taking another step to advance its research and development by creating a subsidiary, Medipure d.o.o., in Croatia.
The Croatian R&D facility will focus on clinical trials and pharmacology. Along with full analytical labs, this site will house a GMP facility allowing the Company to produce drugs in compliance with the European regulatory standards necessary to support clinical trials on the road to regulatory approvals and commercialization.
Vancouver, BC – Medipure Holdings Inc. has taken the next step to advance its research and development by creating a subsidiary, Medipure LifeSciences India (MLSI) Pvt Ltd.